World's largest maker of precision weighing and analytical instruments used in labs, manufacturing and food retail.
World's largest maker of precision weighing and analytical instruments used in labs, manufacturing and food retail.
Sells high-precision scales and analyzers mainly through its own salespeople and service engineers, and earns repeat income from servicing, calibration and consumables on instruments it has installed. Customers in drug and food manufacturing often have to validate the instruments they use, which makes replacing a working one slow.
Moat: wide (installed base, switching costs, brand). Leading precision-instrument brand with a direct global sales/service network that locks in service revenue.
Headquarters: Columbus, Ohio, USA · Founded: 1945 · Employees: 18,100
Size Mettler Toledo (MTD) is a United States Health Care company (Medical Specialties) with a market value of $34.6B, the 328th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1,737 on 18 Nov 2026.
Performance Over six months the shares gained 60.5%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +7.5%); the operating margin is 28.6% (peer median 20.4%).
Valuation It trades at 33.7× forward earnings against a peer median of 27.5× (6th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 35.6 points above its cost of capital (10.6% WACC).
Short interest Short interest is 3.1% of the free float (30 Oct 2026).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.20B | $4.03B | $3.87B | $3.79B | $3.92B |
| Revenue growth | — | +4% | +2% | -3% | — |
| Gross profit | $2.46B | $2.32B | $2.25B | $2.17B | $2.24B |
| EBITDA | $1.33B | $1.24B | $1.25B | $1.20B | $1.24B |
| Net income | $934M | $869M | $863M | $789M | $873M |
| Free cash flow | $871M | $849M | $864M | $861M | $738M |
| Capital expenditure | $114M | $107M | $104M | $105M | $121M |
| Total debt | $2.02B | $2.27B | $2.13B | $2.20B | $2.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mettler Toledo MTD | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Sartorius SRT.DE | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MTD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | +7.0% | 11th highest of 21 |
| 6-month return | +60.5% | +26.4% | highest of 21 |
| Distance from 52-week high | -3.8% | -7.0% | 9th highest of 21 |
| Revenue growth (TTM) | +6.5% | +7.5% | 10th lowest of 21 |
| Operating margin | 28.6% | 20.4% | 4th highest of 21 |
| Forward P/E | 33.7× | 27.5× | 6th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 20.1% | 15.0% | 8th most demanding of 21 |
| Growth delivered (Del g) | +5.5% | +8.9% | 4th lowest of 21 |
| Hurdle (Req g minus delivered) | +14.7 pp | +3.7 pp | 8th most demanding of 21 |
| ROIC minus cost of capital | +35.6 pp | +3.9 pp | highest of 21 |
| EV / EBITDA | 27.5× | 20.2× | 4th most expensive of 20 |
| Net debt / EBITDA | 1.5× | 1.0× | 8th most indebted of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% | +8.7% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |